mouse breast cancer cell line emt6 Search Results


cell lines 414 emt6  (ATCC)
99
ATCC cell lines 414 emt6
Cell Lines 414 Emt6, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+emt6/EMT6/ppr0424193-150-2-13
Average 99 stars, based on 1 article reviews
cell lines 414 emt6 - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
emt6 tumor bearing mice  (Miltenyi Biotec)
98
Miltenyi Biotec emt6 tumor bearing mice
A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or <t>EMT6)</t> were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.
Emt6 Tumor Bearing Mice, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+emt6/C+Tubes/pmc10159910-79-6-17
Average 98 stars, based on 1 article reviews
emt6 tumor bearing mice - by Bioz Stars, 2026-09
98/100 stars
  Buy from Supplier
emt6/ar1 tumour-bearing balb/c mice  (Japan SLC inc)
90
Japan SLC inc emt6/ar1 tumour-bearing balb/c mice
A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or <t>EMT6)</t> were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.
Emt6/Ar1 Tumour Bearing Balb/C Mice, supplied by Japan SLC inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+emt6/emt6+ar1+tumour+bearing+balb+c+mice/10__1016_slash_j__cej__2024__156378-87-1-24
Average 90 stars, based on 1 article reviews
emt6/ar1 tumour-bearing balb/c mice - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mouse mammary adenocarcinoma cells emt6  (China Center for Type Culture Collection)
90
China Center for Type Culture Collection mouse mammary adenocarcinoma cells emt6
A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or <t>EMT6)</t> were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.
Mouse Mammary Adenocarcinoma Cells Emt6, supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+emt6/balb+c+mouse+mammary+carcinoma+cell+line+emt+6/pmc07325461-32-0-9
Average 90 stars, based on 1 article reviews
mouse mammary adenocarcinoma cells emt6 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
drug-resistant mouse mammary tumour (emt6/ar1) cells  (KAC Co Ltd)
90
KAC Co Ltd drug-resistant mouse mammary tumour (emt6/ar1) cells
A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or <t>EMT6)</t> were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.
Drug Resistant Mouse Mammary Tumour (Emt6/Ar1) Cells, supplied by KAC Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+emt6/murine+colorectal+epithelial+cmt93+69+cells/10__1016_slash_j__cej__2024__156378-69-1-9
Average 90 stars, based on 1 article reviews
drug-resistant mouse mammary tumour (emt6/ar1) cells - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
cell line type mouse strain origin emt 6 breast carcinoma balb c atcc ll 2  (ATCC)
99
ATCC cell line type mouse strain origin emt 6 breast carcinoma balb c atcc ll 2
A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or <t>EMT6)</t> were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.
Cell Line Type Mouse Strain Origin Emt 6 Breast Carcinoma Balb C Atcc Ll 2, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+emt6/LL%2F2/us10744167-804-53-63
Average 99 stars, based on 1 article reviews
cell line type mouse strain origin emt 6 breast carcinoma balb c atcc ll 2 - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
emt6 lm2 in vivo target inhibition female athymic nu nu mice  (Charles River Laboratories)
86
Charles River Laboratories emt6 lm2 in vivo target inhibition female athymic nu nu mice
A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or <t>EMT6)</t> were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.
Emt6 Lm2 In Vivo Target Inhibition Female Athymic Nu Nu Mice, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+emt6/balb+c+mice/10__4172_slash_2376___0311__1000140-239-2-17
Average 86 stars, based on 1 article reviews
emt6 lm2 in vivo target inhibition female athymic nu nu mice - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
mouse melanoma line  (ATCC)
97
ATCC mouse melanoma line
A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or <t>EMT6)</t> were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.
Mouse Melanoma Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+emt6/B16-F10%3B+Melanoma%3B+Mouse/pmc00016849-55-55-72
Average 97 stars, based on 1 article reviews
mouse melanoma line - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
emt-6 tumor-bearing mice  (GemPharmatech Co Ltd)
90
GemPharmatech Co Ltd emt-6 tumor-bearing mice
A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or <t>EMT6)</t> were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.
Emt 6 Tumor Bearing Mice, supplied by GemPharmatech Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+emt6/emt+6+tumor+bearing+mice/pm39780388__ja4c14264_si_001-195-1-15
Average 90 stars, based on 1 article reviews
emt-6 tumor-bearing mice - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
emt6mammary carcinoma  (ATCC)
95
ATCC emt6mammary carcinoma
A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or <t>EMT6)</t> were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.
Emt6mammary Carcinoma, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+emt6/EMT6%3B+Mammary+Carcinoma%3B+Mouse/pm37129946-91-1-19
Average 95 stars, based on 1 article reviews
emt6mammary carcinoma - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier
mouse mammary carcinoma emt-6  (InVivos Pte Ltd)
90
InVivos Pte Ltd mouse mammary carcinoma emt-6
A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or <t>EMT6)</t> were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.
Mouse Mammary Carcinoma Emt 6, supplied by InVivos Pte Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+emt6/mouse+mammary+carcinoma+emt+6/pmc05386732-135-4-13
Average 90 stars, based on 1 article reviews
mouse mammary carcinoma emt-6 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
mouse-derived cancer cell line b16f10  (Japan SLC inc)
90
Japan SLC inc mouse-derived cancer cell line b16f10
A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or <t>EMT6)</t> were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.
Mouse Derived Cancer Cell Line B16f10, supplied by Japan SLC inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+breast+cancer+cell+line+emt6/b16bl6+cells/us09753038-570-23-45
Average 90 stars, based on 1 article reviews
mouse-derived cancer cell line b16f10 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or EMT6) were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.

Journal: Cancer immunology research

Article Title: Hedgehog signaling regulates Treg to Th17 conversion through metabolic rewiring in breast cancer

doi: 10.1158/2326-6066.CIR-22-0426

Figure Lengend Snippet: A. Schematic of in vivo experimental timeline. Briefly, tumor-bearing mice (E0771, 4T1, or EMT6) were treated with Smo-i or Veh 3 times per week for three weeks via oral gavage. B. UMAPs of immune and tumor cell clusters (left) and T cell subsets (right) identified from scRNA-seq analysis of 4T1 mammary tumors from mice treated +/− Smo-i. C. Heatmap depicting relative expression of Hh pathway gene expression in T cell subsets from scRNA-seq analysis. D. Foxp3 expression in T cell cluster from 2 representative Smo-i or vehicle treated mice. E. Flow cytometric contour plots and quantitation of 4T1 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=15 mice per group for tumors and 8 mice per group for spleens. F. Flow cytometric contour plots and quantitation of EMT6 tumor infiltrating (top) and splenic (bottom) Treg populations (% positive Foxp3 out of CD4 + T cells). Independent experiments were performed at least twice. N=12 mice per group for tumors and 5 mice per group for spleens. G. Line plots representing Teff proliferation and CFSE intensity of CD4 + Teffs from Treg suppression assay from tumors (top) or spleens (bottom) of 4T1 tumor bearing mice or H. EMT6 tumor bearing mice treated +/− Smo-i. Treg suppression assays were performed twice from 4T1 model and once from EMT6 model. For Treg suppression assay, Tregs were pooled from 10 tumor bearing mice per treatment group. All data is from Tregs differentiated within the tumor or spleens of tumor bearing mice.

Article Snippet: Mammary tumors from 4T1, E0771, or EMT6 tumor bearing mice were harvested, and immediately placed in C-Tubes (Miltenyi Biotec) containing fresh DMEM (Life Technologiess) medium with tumor dissociation enzymes from the mouse tumor dissociation kit (Miltenyi Biotec).

Techniques: Activity Assay, In Vivo, Expressing, Gene Expression, Quantitation Assay, Suppression Assay

A. Flow cytometric quantitation of 4T1 tumor infiltrating Tr17 populations from 4T1 tumor-bearing mice treated with Smo-i or Veh for 3 weeks (% positive IL-17a + Rorγt + out of Tregs, n=9 per treatment group), and B. Inflammatory Tr17 populations from the 4T1 tumor (% positive IFN-γ + or GM-CSF + out of Tr17s, n=7 per treatment group), and Ki-67 expression in these populations (n=5 per treatment group) and C,D spleen (n=8 per treatment group for Tr17s and inflammatory Tr17s, n=5 per treatment group for Ki-67+ Tr17s and inflammatory Tr17s. E. Flow cytometric quantitation of EMT6 tumor infiltrating Tr17 populations (n=7 per treatment group), and F. inflammatory Tr17 populations from the EMT6 tumor (n=7 per treatment group), and G,H. Spleen (n=7 per treatment group). Data in A-H plotted as +/− SEM. I. Flow cytometric quantitation of Th17 markers in iTregs treated with Hhi during differentiation (% positive IL-17a + Rorγt + out of Tregs, n=3 per treatment group). J. qRT-PCR analysis of transcript levels of Il17a and Rorc in iTregs, where Hhi is incorporated into the differentiation cocktail (n=3 per treatment group). K. Flow cytometric quantitation of Th17 inflammatory markers in iTregs treated with Hhi during differentiation (% positive IFN-γ + or GM-CSF + out of Tr17s, n=3 per treatment group). L. Flow cytometric quantitation of Th17 markers in iTregs treated with Hhi for 24 hours after differentiation (n=3 per treatment group). M. qRT-PCR analysis of transcript levels of Il17a and Rorc in iTregs, where Hhi is incorporated for 24 hours after differentiation (n=3 per treatment group). N. Flow quantitation of inflammatory markers in iTregs treated with Hhi after differentiation (n=3 per treatment group). All qRT-PCR data is plotted as fold change +/− SD. In vivo experiments A-D were repeated at least twice. In vivo experiments E-H were performed once. Ex vivo experiments I-N were performed once and T cells were pooled from 20 mice. Hhi (GANT61) was used at 20μM for all ex vivo experiments.

Journal: Cancer immunology research

Article Title: Hedgehog signaling regulates Treg to Th17 conversion through metabolic rewiring in breast cancer

doi: 10.1158/2326-6066.CIR-22-0426

Figure Lengend Snippet: A. Flow cytometric quantitation of 4T1 tumor infiltrating Tr17 populations from 4T1 tumor-bearing mice treated with Smo-i or Veh for 3 weeks (% positive IL-17a + Rorγt + out of Tregs, n=9 per treatment group), and B. Inflammatory Tr17 populations from the 4T1 tumor (% positive IFN-γ + or GM-CSF + out of Tr17s, n=7 per treatment group), and Ki-67 expression in these populations (n=5 per treatment group) and C,D spleen (n=8 per treatment group for Tr17s and inflammatory Tr17s, n=5 per treatment group for Ki-67+ Tr17s and inflammatory Tr17s. E. Flow cytometric quantitation of EMT6 tumor infiltrating Tr17 populations (n=7 per treatment group), and F. inflammatory Tr17 populations from the EMT6 tumor (n=7 per treatment group), and G,H. Spleen (n=7 per treatment group). Data in A-H plotted as +/− SEM. I. Flow cytometric quantitation of Th17 markers in iTregs treated with Hhi during differentiation (% positive IL-17a + Rorγt + out of Tregs, n=3 per treatment group). J. qRT-PCR analysis of transcript levels of Il17a and Rorc in iTregs, where Hhi is incorporated into the differentiation cocktail (n=3 per treatment group). K. Flow cytometric quantitation of Th17 inflammatory markers in iTregs treated with Hhi during differentiation (% positive IFN-γ + or GM-CSF + out of Tr17s, n=3 per treatment group). L. Flow cytometric quantitation of Th17 markers in iTregs treated with Hhi for 24 hours after differentiation (n=3 per treatment group). M. qRT-PCR analysis of transcript levels of Il17a and Rorc in iTregs, where Hhi is incorporated for 24 hours after differentiation (n=3 per treatment group). N. Flow quantitation of inflammatory markers in iTregs treated with Hhi after differentiation (n=3 per treatment group). All qRT-PCR data is plotted as fold change +/− SD. In vivo experiments A-D were repeated at least twice. In vivo experiments E-H were performed once. Ex vivo experiments I-N were performed once and T cells were pooled from 20 mice. Hhi (GANT61) was used at 20μM for all ex vivo experiments.

Article Snippet: Mammary tumors from 4T1, E0771, or EMT6 tumor bearing mice were harvested, and immediately placed in C-Tubes (Miltenyi Biotec) containing fresh DMEM (Life Technologiess) medium with tumor dissociation enzymes from the mouse tumor dissociation kit (Miltenyi Biotec).

Techniques: Quantitation Assay, Expressing, Quantitative RT-PCR, In Vivo, Ex Vivo

A. Il17a expression from scRNA-seq analysis in the lymphocyte cluster from representative Smo-i treated or Veh treated 4T1 tumor-bearing mice. B. Heatmap of Th17 related genes in Th17s from scRNA-seq analysis from vehicle or Smo-i treated 4T1 tumor-bearing mice. C. Flow cytometric quantitation of 4T1 tumor infiltrating populations from mice treated with Veh or Smo-i from left to right: i) Th17 populations (% positive IL-17a+ Rorγt+ out of CD4+ T cells, n=12 per treatment group), ii) inflammatory Th17 populations from the tumor (% positive IFN-γ + or GM-CSF + out of Th17s, n=7 per treatment group), and Ki-67 expression in iii) Th17s (n=5 per treatment group) and iv) inflammatory Th17s (n=5 per treatment group). D. Flow cytometric quantitation of 4T1 tumor bearing mice splenic populations from left to right: i) splenic Th17 populations (% positive IL-17a + Rorγt + out of CD4 + T cells, n=7 per treatment group), ii) splenic inflammatory Th17 populations from the tumor (% positive IFN-γ+ or GM-CSF+ out of Th17s, n=7 per treatment group), and Ki-67 expression in iii) splenic Th17s (n=5 per treatment group) and iv) splenic inflammatory Th17s (n=5 per treatment group). E. Flow cytometric quantitation of EMT6 tumor infiltrating Th17 populations (left, n=7 per treatment group) and (right) inflammatory Th17 populations (n=7 per treatment group) and F. Splenic Th17 populations (left n=7 per treatment group) and (right) inflammatory Th17 populations (n=7 per treatment group). In vivo experiments C-D were performed at least twice. In vivo experiments E-F were performed once. Data plotted as +/− SEM.

Journal: Cancer immunology research

Article Title: Hedgehog signaling regulates Treg to Th17 conversion through metabolic rewiring in breast cancer

doi: 10.1158/2326-6066.CIR-22-0426

Figure Lengend Snippet: A. Il17a expression from scRNA-seq analysis in the lymphocyte cluster from representative Smo-i treated or Veh treated 4T1 tumor-bearing mice. B. Heatmap of Th17 related genes in Th17s from scRNA-seq analysis from vehicle or Smo-i treated 4T1 tumor-bearing mice. C. Flow cytometric quantitation of 4T1 tumor infiltrating populations from mice treated with Veh or Smo-i from left to right: i) Th17 populations (% positive IL-17a+ Rorγt+ out of CD4+ T cells, n=12 per treatment group), ii) inflammatory Th17 populations from the tumor (% positive IFN-γ + or GM-CSF + out of Th17s, n=7 per treatment group), and Ki-67 expression in iii) Th17s (n=5 per treatment group) and iv) inflammatory Th17s (n=5 per treatment group). D. Flow cytometric quantitation of 4T1 tumor bearing mice splenic populations from left to right: i) splenic Th17 populations (% positive IL-17a + Rorγt + out of CD4 + T cells, n=7 per treatment group), ii) splenic inflammatory Th17 populations from the tumor (% positive IFN-γ+ or GM-CSF+ out of Th17s, n=7 per treatment group), and Ki-67 expression in iii) splenic Th17s (n=5 per treatment group) and iv) splenic inflammatory Th17s (n=5 per treatment group). E. Flow cytometric quantitation of EMT6 tumor infiltrating Th17 populations (left, n=7 per treatment group) and (right) inflammatory Th17 populations (n=7 per treatment group) and F. Splenic Th17 populations (left n=7 per treatment group) and (right) inflammatory Th17 populations (n=7 per treatment group). In vivo experiments C-D were performed at least twice. In vivo experiments E-F were performed once. Data plotted as +/− SEM.

Article Snippet: Mammary tumors from 4T1, E0771, or EMT6 tumor bearing mice were harvested, and immediately placed in C-Tubes (Miltenyi Biotec) containing fresh DMEM (Life Technologiess) medium with tumor dissociation enzymes from the mouse tumor dissociation kit (Miltenyi Biotec).

Techniques: Derivative Assay, Expressing, Quantitation Assay, In Vivo

A. Fold change of CD8 + T cell recruiting chemokine transcript expression in 4T1 tumor infiltrating Th17s from scRNA-seq analysis of tumor from 4T1 tumor-bearing mice treated with Veh or Smo-i. B. Fold change of CD8 + T cell recruiting chemokine receptor transcript expression in 4T1 tumor infiltrating CD8 + T cells and C. cytotoxic T cells from scRNA-seq analysis. D. Flow cytometric quantitation of 4T1 tumor infiltrating CD8 + T cells from mice treated with Veh or Smo-i (n=15 per treatment group) and splenic total CD8 + T cells (n=12 per treatment group). E. Flow cytometric quantitation of EMT6 tumor infiltrating CD8 + T cells (n=5 per treatment group) and splenic total CD8 + T cells (n=7 per treatment group) F. 4T1 tumor infiltrating (n=10 per treatment group) and splenic cytotoxic CD8 + T cells (n=7 per treatment group) (% positive GZMB+ out of CD8 + T cells), and G. EMT6 tumor infiltrating (n=12 per treatment group) and splenic (n=7 per treatment group) cytotoxic CD8 + T cells. H. GO pathway analysis of migration pathways significantly enriched in CD8 + T cells and I. cytotoxic CD8 + T cells from Smo-i treated mice. Rich factor is calculated using the following formula: # of differentially-expressed genes divided by total genes within GO term or pathway. J. Flow cytometric quantitation of 4T1 tumor and spleen infiltrating inflammatory CD8 + T cells (% positive IFN-γ+ out of CD8 + T cells). K. Schematic for in vivo adoptive transfer experiment. L. Flow cytometric quantitation of 4T1 tumor (n=5 Vehicle and 7 treated) and spleen infiltrating (n=5 vehicle and 7 treated) total CD8 + T cells, CD8 + CD45.1 + cells, CD8 + CD45.2 + cells, and CD8 + CD45.2 + GZMB + cells, represented as number of cells per million total cells. In vivo experiments D-G were performed at least twice. In vivo experiments in J and L were performed once. Data plotted as +/− SEM.

Journal: Cancer immunology research

Article Title: Hedgehog signaling regulates Treg to Th17 conversion through metabolic rewiring in breast cancer

doi: 10.1158/2326-6066.CIR-22-0426

Figure Lengend Snippet: A. Fold change of CD8 + T cell recruiting chemokine transcript expression in 4T1 tumor infiltrating Th17s from scRNA-seq analysis of tumor from 4T1 tumor-bearing mice treated with Veh or Smo-i. B. Fold change of CD8 + T cell recruiting chemokine receptor transcript expression in 4T1 tumor infiltrating CD8 + T cells and C. cytotoxic T cells from scRNA-seq analysis. D. Flow cytometric quantitation of 4T1 tumor infiltrating CD8 + T cells from mice treated with Veh or Smo-i (n=15 per treatment group) and splenic total CD8 + T cells (n=12 per treatment group). E. Flow cytometric quantitation of EMT6 tumor infiltrating CD8 + T cells (n=5 per treatment group) and splenic total CD8 + T cells (n=7 per treatment group) F. 4T1 tumor infiltrating (n=10 per treatment group) and splenic cytotoxic CD8 + T cells (n=7 per treatment group) (% positive GZMB+ out of CD8 + T cells), and G. EMT6 tumor infiltrating (n=12 per treatment group) and splenic (n=7 per treatment group) cytotoxic CD8 + T cells. H. GO pathway analysis of migration pathways significantly enriched in CD8 + T cells and I. cytotoxic CD8 + T cells from Smo-i treated mice. Rich factor is calculated using the following formula: # of differentially-expressed genes divided by total genes within GO term or pathway. J. Flow cytometric quantitation of 4T1 tumor and spleen infiltrating inflammatory CD8 + T cells (% positive IFN-γ+ out of CD8 + T cells). K. Schematic for in vivo adoptive transfer experiment. L. Flow cytometric quantitation of 4T1 tumor (n=5 Vehicle and 7 treated) and spleen infiltrating (n=5 vehicle and 7 treated) total CD8 + T cells, CD8 + CD45.1 + cells, CD8 + CD45.2 + cells, and CD8 + CD45.2 + GZMB + cells, represented as number of cells per million total cells. In vivo experiments D-G were performed at least twice. In vivo experiments in J and L were performed once. Data plotted as +/− SEM.

Article Snippet: Mammary tumors from 4T1, E0771, or EMT6 tumor bearing mice were harvested, and immediately placed in C-Tubes (Miltenyi Biotec) containing fresh DMEM (Life Technologiess) medium with tumor dissociation enzymes from the mouse tumor dissociation kit (Miltenyi Biotec).

Techniques: Activity Assay, Expressing, Quantitation Assay, Migration, In Vivo, Adoptive Transfer Assay